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Abstract
Background: Evaluation of cystic fibrosis transmembrane conductance regulator (CFTR) functional activity to assess new
therapies and define diagnosis of cystic fibrosis (CF) is cumbersome. It is known that leukocytes express detectable levels of
CFTR but the molecule has not been characterized in these cells. In this study we aim at setting up and validating a blood
test to evaluate CFTR expression and function in leukocytes.
Description: Western blot, PCR, immunofluorescence and cell membrane depolarization analysis by single-cell fluorescence
imaging, using the potential-sensitive DiSBAC2(3) probe were utilized. Expression of PKA phosphorylated, cell membrane-
localized CFTR was detected in non-CF monocytes, being undetectable or present in truncated form in monocytes derived
from CF patients presenting with nonsense mutations. CFTR agonist administration induced membrane depolarization in
monocytes isolated from non-CF donors (31 subjects) and, to a lesser extent, obligate CFTR heterozygous carriers (HTZ: 15
subjects), but it failed in monocytes from CF patients (44 subjects). We propose an index, which values in CF patients are
significantly (p,0.001) lower than in the other two groups. Nasal Potential Difference, measured in selected subjects had
concordant results with monocytes assay (Kappa statistic 0.93, 95%CI: 0.80–1.00).
Results and Significance: CFTR is detectable and is functional in human monocytes. We also showed that CFTR-associated
activity can be evaluated in 5 ml of peripheral blood and devise an index potentially applicable for diagnostic purposes and
both basic and translational research: from drug development to evaluation of functional outcomes in clinical trials.
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Introduction
Cystic fibrosis (CF) is primarily a disorder of electrolyte
transport by epithelial cells in which an anion channel, activated
by cyclic adenosine monophosphate (cAMP)-dependent kinase
(the cystic fibrosis transmembrane conductance regulator-CFTR)
is defective and represents the most common autosomal recessive
disease with lethal consequences in Caucasians. Mutations in the
CFTR gene result in aberrant variants that are either unstable,
mis-localized, or with altered chloride conductance [1]. Although
many antibodies have been developed against CFTR, only limited
data describing CFTR expression in human leukocytes are
available. In fact, most studies have focused on selected leukocytes
or cell lines and provide only indirect measurements of CFTR
[2,3]. Functional CFTR is currently evaluated in humans using ex
vivo and in vivo assays, the former method utilizing rectal biopsies
[4]. This approach permits the direct recording of transepithelial
currents (Intestinal Current Measurements, ICM) but requires an
excision of a tissue sample. Nasal potential differences (NPD) [5]
can be measured in vivo but require patient’s collaboration, are
time consuming and can only be performed in highly specialized
centers Both these methods do not allow performing multiple
assessments on the same subject within short intervals. Sweat test
present normal/borderline results in some CF patients as
previously described [6]. Moreover concomitant diseases or
therapies could affect sweat tests [7].
To our best knowledge, only one blood test of potential clinical
interest for the recognition of CF patients (using erythrocytes) has
been proposed. However, this test has limitations in terms of
sensitivity and specificity [8].
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Recently, it has been reported that human alveolar macro-
phages express functional CFTR [9]. Our aim was to confirm and
extend this finding by showing the expression of a specifically
processed CFTR polypeptide in monocytes and to propose a
functional assay using monocytes isolated from peripheral blood.
Materials and Methods
Subjects
Healthy volunteers including obligate heterozygote and indi-
viduals undergone genetic analysis for CFTR mutations for genetic
counseling purposes were recruited for the study.
Peripheral blood was taken from 31 non-CF (median age 39.5
years, range 25–48 years; 12 males and 19 females), 15
heterozygous (HTZ: median age 44 years, range 4–67 years 4; 3
males and 12 females) and 44 CF subjects (median age 32 years,
range 10–50; 23 males and 21 females). Samples and data were
used for analysis only after that informed consent was obtained
according to the guidelines approved by the local Ethical
Committee. All clinical data were collected in the electronic
database of the Cystic Fibrosis Center of Verona.
Purification of monocytes from whole blood
Monocytes were obtained from 4–5 ml of fresh whole blood
supplemented with 1 mM EDTA and purified using the
RosetteSepH Human Monocyte Enrichment Cocktail (cat. #
15068 StemCell Technologies) according to the manufacturer’s
instructions. To remove platelets 20 mL of CD61 MicroBeads (cat.
# 130-051-101 Miltenyi Biotec) was added and cells were
incubated for 15 minutes at 4–8uC and treated according to the
manufacturer’s instructions.
Cell lines
Cell lines utilized were the following: CFBE41o2, (kind gift
from DC Gruenert, California Pacific Medical Center Research
Institute, San Francisco, CA, USA) [10], 16HBE14o- (kindly
provided by P. Davis, Case Western Reserve University School of
Medicine, Cleveland, OH, USA) [11], the bronchial epithelial cell
line IB3-1 derived from a CF patient with genotype W1282X/
F508del (kind gift of Pamela Zeitlin, Johns Hopkins Hospital,
Baltimore, USA) [12], pancreatic cell lines Suit-2 derived from a
liver metastasis of a human pancreatic adenocarcinoma [13] and
CFPAC-1 [14].
Western blotting
Monocytes and epithelial cell lines were lysed with a solution
containing: 150 mM NaCl, 50 mM TrisHCl, 1% (v/v) Triton X-
100, 0.2 mM NaVO4, 1 mM DTT, 10 mM NaF, 1 mM EDTA
and protease inhibitor cocktail (Roche, Milan, Italy). Proteins were
quantified by Bradford method, denaturated in Laemmli sample
buffer for 20 minutes at 40uC or 10 minutes at 95uC, then
separated in SDS gel containing 6% acrylamide and subjected to
western blotting onto nitrocellulose membranes (Millipore Corp.,
Bedford, MA). Membranes with transferred proteins were
incubated over night at +4uC with or 0.3 mg/mL polyclonal
anti-CFTR (ACL-006, Alomone Labs, Jerusalem, Israel) or
0.5 mg/mL of either of the monoclonal anti-CFTR antibodies
clones 13-1 or 24-1 (R&D Systems, Minneapolis, U.S.A). After
stripping, the same membranes were incubated with 0.2 mg/mL
polyclonal anti-actin (Sigma-Aldrich, Missouri, U.S.A). In all cases
detection of the primary antibody was performed with HRP
conjugated secondary antibodies (GE Healthcare, Piscataway,
U.S.A) followed by ECL detection (Millipore, Billerica, U.S.A).
Immunofluorescence
Monocytes were purified as described above and seeded onto
coverslips at a density of 450 cell/mm2. Cells were let to adhere for
one hour and were then fixed for 10 minutes with 4%
paraformaldehyde in PBS (BioLegend, San Diego, U.S.A). After
blocking and permeabilization with 10% human serum and 0.1%
(v/v) TritonHX-100 (both Sigma-Aldrich, Missouri, U.S.A) cells
were incubated with 1 mg/mL monoclonal anti-CFTR antibody
clone 13-1 (R&D Systems, Minneapolis, U.S.A) and then with
2 mg/mL Goat anti-Mouse IgG/AF594 (Invitrogen, Carlsbad,
U.S.A). Nuclei were stained with 3 mM DAPI (Sigma-Aldrich,
Missouri, U.S.A). Cells were analysed at Leica TCS-SP5 confocal
microscope (Leica Microsystem, Wetzlar, Germany).
Immune precipitation and in vitro phosphorylation of
CFTR
306106 cells were washed twice with 50 ml ice cold TBS 16
and resuspended in 1 ml Hypotonic Buffer (10 mM HEPES-
NaOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 2 mM DTT,
1 mM PMSF) in the presence of protease inhibitor cocktail
(Complete Mini, EDTA-free Roche Diagnostics, Mannheim,
Germany) as previously described [15].
200 mg of light membrane preparation was precleared by
adding 100 ml of suspended 20% v/v Protein G-Sepharose 4 Fast
flow conjugate (PGS: GE Healthcare, Uppsala Sweden) and
incubated at 4uC on a rotating wheel for 30 minutes. After
centrifugation at 16,0006g for 30 seconds at 4uC, the supernatant
was transferred, to a new ice-cold microcentrifuge tube containing
2 mg rabbit anti-CFTR (ACL-006 Alomone Labs Ltd., Jerusalem,
Israel; 0.8 mg/ml) and 2 mg mouse anti-CFTR (MAB 3482 clone
MM13-4 Chemicon International, Temecula, California USA;
1 mg/ml) or non-immune rabbit and mouse IgG and incubated
for 2 hours at 4uC. Immune precipitation and in vitro phosphor-
ylation of CFTR After centrifugation at 16,0006g for 10 minutes
at 4uC, the resulting supernatant was transferred to a tube
containing 10 ml of PGS and incubated at 4uC with rotation for
30 minutes. Beads were gently washed 3 times with 1 ml RIPA
Buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% Na deoxycholate,
0.1% SDS, 200 mM Na orthovanadate, 50 mM Tris-HCl pH 7.4,
1 mM DTT, 10 mM NaF, 1 mM EDTA) and once with 1 ml
PKA Buffer (20 mM Tris-HCl pH 7.5, 0.5 mM DTT).
To phosphorylate CFTR, the pellet was resuspended in 50 mL
PKA Buffer containing 250 ng PKA (PKA, HisNTagH, Active,
Human, Recombinant, E. coli Calbiochem, Merck KGaA,
Darmstadt, Germany; specific activity: $500,000 units/mg
protein), 10 mM MgCl2, 10 mM ATP, 10 mCi c
32P-ATP (activity:
6000 Ci/nmol- 150 mCi/ml; Perkin-Elmer, Boston, MA USA)
and incubated at room temperature for 30 minutes. After blocking
the reaction with SDS-PAGE sample buffer, the sample was
subjected to 6% SDS-PAGE. The gel was subsequently stained
with Coomassie blue, dried and exposed to X-OMAT AR film.
CFTR mRNA analysis by reverse-transcription and
polymerase chain reaction (PCR)
Total RNA from monocytes purified as previously described
was prepared using TRIzol extraction kit (Invitrogen, Life
Technologies, Rockville, MD) according to the manufacturer’s
instructions. Primers used were: ACTB 170F, 5-ATCAAGAT-
CATTGCTCCTCCTG-3; ACTB 170R, 5-GCAACTAAGTCA
TAGTCCGCC-3; CFTR 771F 5-GGGGAAGTCACCAAAG-
CAGTACAGC-3; CFTR 771R 5-GCGCAGAACAATGCA-
GAATGAGATGG-3 [16]. These CFTR primers give a predicted
product of 771 bp that was used as template for the following
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PCR, which was performed as above with the following primers
(CFTR 338F 5-TCACATTGGAATGCAGATGAG-3; CFTR
338R 5-GTCTTTCACTGATCTTCCCA-3) expected to amplify
a 338 bp product when exon 5 is present in the cDNA and of
248 bp if the exon 5 is skipped. Total RNA (1 mg) was reverse
transcribed in a volume of 20 ml using 1 mM random primer
(Invitrogen, Milan, Italy) and 200 U SuperScript II (Invitrogen,
Milan, Italy) at 42uC for 1 hour, as described by the manufacturer.
Polymerase chain reaction (PCR) was performed in a GeneAmp
PCR System 9700 (PE Applied Biosystems, Milan, Italy) for 35
cycles (30 seconds of denaturation at 94uC, 30 seconds of
annealing at 60uC, and 50 seconds of elongation at 72uC) in a
volume of 25 mL reaction buffer containing 0.75 U AmpliTaq
(PE Applied Biosystems), 0.4 M each primer, and 0.2 mM dNTPs
(Roche, Milan, Italy). Actin mRNA amplification was performed
for 22 cycles on the cDNA as positive control of reaction
efficiency.
Cell depolarization assay
The potential-sensitive probe bis- (1,3-diethylthiobarbituric
acid) trimethine oxonol (DiSBAC2(3), Invitrogen, USA) was used
to monitor CFTR-dependent membrane potential (Vm) changes
in pancreatic adenocarcinoma cell lines derived from normal or
CF subjects (Suit-2 and CFPAC-1 respectively) and in monocytes
from non-CF, HTZ and CF patients. The DiSBAC2(3) method
has already been described in detail [17], and was used with minor
modifications. Before the assay, monocytes were sedimented
(26105 cells/ml) onto a tissue culture dish (Falcon, Becton
Dickinson, Franklin Lakes, NJ USA) for 1 h in RMPI 1640
medium supplemented with 1 mM L-glutamine at 37uC and then
supplemented with medium containing 10% FBS. At the time of
assay, 24 hours after preparation, the cells were washed twice with
a Cl-free solution. Then, the cells were perfused for 10 minutes at
room temperature with Cl-free solution containing 100 nM
DiSBAC2(3). A baseline was acquired for 5 minutes before
addition of a CFTR stimulus, consisting of a cocktail containing
500 mM 8-Br-cAMP (Sigma B5386), 10 m Forskolin (Sigma F6886)
and 100 mM 3-Isobutyl-1-methylxanthine (Sigma I7018). The
CFTR inhibitor CFTR (inh)-172 (Sigma C2992) was used at a
final concentration of 10 mM to specifically inhibit CFTR activity
[18].
In some experiments amiloride (Sigma A7410) was added to a
final concentration of 200 mM to block epithelial sodium channel.
The fluorescent signal was acquired on Zeiss microscope
Olympus BXS1WI using a CCD intensified videocamera (Retiga
EXi, Q-Imaging, Canada) and the software QED in vivo
(MediaCybernetics, USA), at a rate of 1 frame/min. DiSBAC2(3)
was excited with a 100-watt mercury-arc lamp and 535/40
excitation and 630/30 emission filters.
Data are presented as percentage of signal variation (DF) in
relation to the time of addition of the stimulus, according to the
equation: DFt = [(Ft-F0)/F0]6100, where Ft and F0 are the
fluorescence values in the absence of extracellular Cl- at time t
and at the time of addition of the stimulus, respectively.
Transepithelial NPD measurements
NPD measurements were performed following the standardized
procedure [19] consistent with the recommendations provided by
the SOP and applied following the procedures set with the
multicenter basic protocol [20]. In particular, the potential
difference (PD) was determined by measuring the PD between a
Ringers-filled exploring catheter on the nasal mucosa and a
reference bridge (21-gauge needle filled with Ringers solution)
inserted into the subcutaneous space of the forearm. PE50 tubing
(Fisher Scientific BD) was utilized as catheters. Each nostril was
examined using an otoscope. The inferior turbinate was explored
with a catheter for the site of most negative voltage; the probe was
positioned with tape on the nose and forehead. Baseline PD was
determined by perfusion with Ringers and the responses to
amiloride (161024 M), zero chloride (0 Cl2), isoproterenol
(161025 M) and ATP (161024 M) were sequentially acquired
for a minimum of 3 minutes each obtaining a period of stable
signal for at least 30 sec. We perfused solutions warmed to 37uC
by passing the polyethylene tubing through a water-jacketed tube
proximal to the nasal probe in order to obtain a larger activated
chloride conductance [21]. The software PowerLab (ADInstru-
ments, UK) was utilized for acquisition and analysis of data. The
data acquisition system ML870 PowerLab 8/30 was utilized in
connection with the voltmeter Iso Millivolt Meter (World Precision
Instruments, Sarasota (WPI), FL, USA). It was connected to Ag/
AgCl electrodes MEH3S (World Precision Instruments, FL, USA)
linked to the catheters.
Smokers and subjects with nasal polyps or abnormal mucosa
were not subjected to this test.
Analysis of cell depolarization assay data
Before analysis, data were transformed to control for bias
potentially generated by experimental setting variation: fluores-
cence was expressed as % variation between time t and time 0
according to the formula: DFt = [(Ft-F0)/F0]6100. The first 5 time
points were excluded from the analysis due to the perturbation of
the system as a consequence to the addition of compounds that
required the system to reach equilibrium before starting the
recording.
The % variation of fluorescence over time and 3 phenotypic
groups (CF, non-CF and HTZ) and their interaction were fitted
with a mixed linear model including individual response curves as
random term.
Q-Q plots of residuals and plots of residuals against predicted
values were inspected to check whether model assumptions were
met.
We propose a summary measure of the DFt curves, computed as
difference between the mean DFt (stimulus), and the mean DFt
(vehicle) in the last five minutes of recording, as described. We
termed this value ‘‘CF index’’.
To test whether CF index values differ between phenotypic
groups or between classes of CFTR mutation, analysis of variance
was performed on normal scores computed on CF-index ranks
[22]. Statistical significance was set at the level of P,0.05.
Bonferroni procedure [23] was used to adjust p-values when
multiple tests were carried out. Analyses were performed with SAS
9.2 (SAS Institute, Inc., Cary, NC).
Results
CFTR expression in epithelial cells and monocytes
Western blotting analysis of cell lysates from pancreatic and
bronchial epithelial cell lines expressing wild-type CFTR (Suit-2
and 16HBE14o-) allows to identify the presence of all the major
CFTR bands described in the literature, namely bands A, B and C
(Figure 1A). The CFTR isoform A corresponds to a MW of
approximately 130–140 kDa corresponding to an immature,
incompletely-glycosylated form of CFTR as shown in 16HBE14o-
and CFPAC-1 cell lines [24] (Figure 1, panels A and B). Another
isoform (isoform B) is also typical of the incompletely glycosylated
(‘‘core glycosylated’’) CFTR expressed by F508del/F508delex-
pressing cells as shown for CFBE41o2 while the fully glycosylated
form (C) is also detectable (Figure 1, panel B). The apparent
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MW of CFTR expressed by CF pancreatic epithelial cell line
CFPAC-1 corresponds to that of band A expressed by 16HBE14o-
and by human monocytes as detected by ACL-006 antibody
(Figure 1, panel A).
All three antibodies utilized recognize different epitopes present in
all CFTR forms expressed in epithelial cells but present with a
slightly different pattern, likely based also on the type and extent of
post-translational processing. CFTR expressed in monocytes is
present in all the known forms (A, B and C), however none of the
individual antibodies appear capable to recognize all the forms
expressed by monocytes as it occurs (albeit at different extent) in
epithelial cells. Indeed ACL-006 antibody detects in monocytes
bands A and (inconstantly) C, 24-1 bands A and B while 13-1
recognize band C.When the data are combined, all the differentially
processed forms of CFTR appear to be expressed by monocytes. Of
note, CFTR is usually detected in epithelial cells upon treatment of
the cell lysates at room temperature or 40uC [25]. We did confirm
these observations in epithelial cells (Figure 1 panel B), however we
discovered that CFTR expressed in monocytes is detectable only
when cell lysates are treated at 95uC. Treatment at 40uC apparently
induces protein degradation as suggested by the reduced expression
of actin in the same lysates incubated in reducing sample buffer at
40uC in comparison with the same sample treated at 95uC where
complete protein denaturation (and protease inactivation) are known
to occur (Figure 1, panel B, last two lanes).
The monocytes express the same mRNA form detectable in
epithelial cells as demonstrated by RT-PCR on the same cells
analyzed by western blotting with primers located on exons 4 and
6. These primers amplify the region containing exon 5, known to
be excluded in a 140 kDa partially functional CFTR isoform
detected in human cardiac muscle [26] (Figure 1, panel B).
The specificity of the signal detected with the antibodies is
further strengthened by the observation of the loss of the C-
terminal epitope in monocytes derived from patients carrying
two nonsense mutations (R1158X/E585X; R1162X/R1162X).
CFTR expression is also severely impaired in monocytes derived
from patients with F508del/F508del genotypes as expected
(Figure 1, panel C).
We next wondered whether CFTR was properly expressed on
the plasma membrane of monocytes. To answer to this point we
applied the combination of a biochemical assay with confocal
microscopy analysis. The immunoprecipitated CFTR protein
expressed in peripheral blood leukocytes (monocytes, lymphocytes
and, albeit at lower levels, granulocytes) is detectable in the
membrane fraction where it represents an in vitro substrate for the
catalytic subunit of protein kinase A (Figure 2, panel A).
The membrane localization of CFTR expressed by non-CF
monocytes is confirmed by confocal microscopy analysis (Figure 2,
bottom right panel), where non-CF monocytes expressing
membrane-localized CFTR are shown in comparison with the
monocytes isolated from patients carrying a R1162X/R1162X,
predicted to produce a truncated form of the protein as confirmed
by western blotting data (Figure 1, panel C) that appears to
loose membrane localization, as detected by confocal microscopy
analysis (Figure 2, bottom left panel).
Altogether these data indicate that monocytes express a CFTR
polypeptide with biochemical features slightly different from those
expressed by epithelial cells, but possessing all the features deemed
necessary for a functional channel [2,9,24].
CFTR functional analysis in epithelial cell lines and
primary monocytes by single cell fluorescence analysis
To evaluate the functional activity of CFTR expressed in
leukocytes we applied a method based on membrane potential
(Vm) changes in single-cell, detected by the fluorescent probe bis-
(1,3-diethylthiobarbituric acid) trimethine oxonol (DiSBAC2(3)), a
member of the slow dye family [17]. The fluorescence quantum
efficiency of DiSBAC2(3) increases when the dye moves from
aqueous solution into membranes. A change in Vm, as for
example during a depolarization, results in additional transfer of
the dye into membranes, thus increasing the fluorescent signal.
The experimental conditions for the CFTR functional assay were
established using the Suit-2 and CFPAC-1 pancreatic cancer cell
lines by measuring the membrane depolarization induced by
treatment with the cAMP analog 8-Br-cAMP (stimulus), control
baseline was recorded with the addition of vehicle alone (vehicle).
8-Br-cAMP induced a rapid fluorescence increase in Suit-2 cells,
that was almost completely inhibited by treatment with the CFTR
inhibitor CFTR (inh)-172 [18], while in CFPAC-1, a pancreatic
adenocarcinoma cell line derived from a patient affected by CF
(F508del/F508del genotype) cAMP analog was not able to induce
fluorescence changes (Figure 3A).
In non-CF monocytes the stimulus induced a membrane
depolarization that was completely reversed by CFTR (inh)-172
(Figure 3B, a). In the cells derived from HTZ subjects, the
increase in fluorescence following stimulation was substantially
lower than that detected in non-CF (Figure 3B, c). Monocytes
isolated from CF subjects (listed in Table 1) responded to
Figure 1. Expression of CFTR in epithelial cells and monocytes. Panel A: Monocyte cell lysates were denatured at 95uC while epithelial cells
were treated at 40uC before SDS-PAGE. The left panel shows the result after the incubation with the anti- CFTR antibody ACL-006, 24-1 or 13-1.
Although in epithelial cells all the CFTR forms (A, B and C) are detected (although with a different pattern of reactivity depending on the type of
antibody), in monocytes not all the bands are detected by the individual antibodies, although all of them are present as testified by the recognition of
bands A, B and C by their combination. While band A is consistently detected by ACL-006 antibody in monocytes, detection of the other bands with
this antibody is not reproducible in all the samples tested. On the right side of the panel the arrow indicates the less glycosylated form of CFTR (band
A) expressed in 16HBE14o- cells, CFPAC-1 and monocytes (ACL-006 antibody). mRNA of CFTR as detected by RT-PCR is expressed by monocytes that
express the same spliced isoform expressed by epithelial cells. Actin (ACTB) has been amplified as control. Panel B: Temperature-dependent
detection of CFTR Effect of the denaturating temperature on the CFTR bands detected in epithelial cells and monocytes. A major band around
170 kDa (band C) is detected in both epithelial cells lines expressing wild-type CFTR (Suit 2 and 16HBE14o-) and in monocytes (13-1 antibody).
CFBE41o2 (CFBE) (F508del/F508del) cells express a single band corresponding to a core-glycosylated CFTR (band B, ACL-006 and 24-1 antibodies)
while CFTR expression level in IB3-1 (W1282X/F508del) is below the detection limit of the assay for ACL-006 antibody but display a band using the 24-
1 antibody. The incubation with ACL-006, 24-1 and 13-1 antibodies, reactive against a C- and a more N-terminal epitope (13-1), when analyzed
together, identify all the glycosylated forms in our assay only when the most appropriate temperature is utilized (40uC for epithelial cells and 95uC for
monocytes). Of note is the loss of CFTR signal in monocytes treated at 40uC associated to a reduction of immunoreactivity of anti-actin antibody used
to demonstrate equal protein load (last two lanes, right). Panel C: Western blotting with the indicated antibodies on lysates of monocytes derived
from patients with the indicated genotypes. Note that the bands corresponding to a full length CFTR present in wild-type (WT) or obligate
heterozygotes (WT/Q39X) are missing in monocytes derived from patients homozygous for nonsense mutations (13-1 antibody). Patients carrying
one or two F508del alleles express a much fainter band. Actin expression is shown to demonstrate equal protein load.
doi:10.1371/journal.pone.0022212.g001
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stimulation with a decrease of the baseline fluorescence signal, and
thus the response was below the baseline of spontaneous
depolarization indicating a defect in the membrane conductance
(Figure 3B, b). This effect was highly reproducible and was
sensitive to the sodium channels blocker amiloride (Figure 4),
suggesting their involvement in this phenomenon.
Analysis of fluorescence over time by phenotypic group
and proposal of an index (CF-index) to differentiate non-
CF, HTZ and CF subjects
As figure 3B (panels a–c) shows, DFt (vehicle) increases over
time in the CF group, whereas it remains almost unchanged in the
non-CF and HTZ groups. Conversely, DFt (stimulus) does not
change over time in the CF group, taking values around zero and
constantly increases over time in the non-CF group. Interestingly,
the DFt (stimulus) curve of HTZ group runs between the CF and
the non-CF group.
The differences DFt (stimulus) – DFt (vehicle) was calculated and
the results were named ‘‘CF-index’’. Statistical analysis of the data
performed in the three groups confirmed the presence of a
decreasing trend over time in this difference in the CF group
(p,0.0001) and the increasing trend in the non-CF (p,0.0001)
and in the HTZ (p= 0.04) groups. The analysis further confirmed
the difference in the DFt (stimulus) – DFt (vehicle) curve between
the groups CF and non-CF (p,0.0001), between the CF and HTZ
(p,0.0001) and the non-CF and HTZ (p= 0.02) groups.
Figure 3B (panel d) shows the distribution of CF-index values
in the three phenotypic groups. CF group showed values of CF-
index significantly lower (median: 270.2, IQR: 2113.7, 247.5)
both than the HTZ group (median: 50.5; IQR: 17.8, 84.7) and the
non-CF group (median: 113.3, IQR: 57.3, 147.3), both p,0.001;
also the difference found between the non-CF and HTZ groups
was statistically significant (p = 0.015).
However, the ROC curve computed on CF-index values for
HTZ and non-CF participants showed poor ability of CF-index to
discriminate between these groups (Figure S1).
The CFTR inhibitor 172 inhibits the depolarization induced by
stimulation of non-CF monocytes (Figure 4).
To ascertain whether CFTR mutations have an impact on the
values of the CF-index, we classified the mutations of CF patients
into classes. Analysis of variance revealed that there is no evidence
Figure 2. Expression of CFTR in leukocytes. Upper Panel: Membrane localization of CFTR in leukocytes. CFTR was immune-purified from
200 mg of light membrane samples of non-CF lymphocytes, monocytes and neutrophils using a mixture of two anti-CFTR antibodies (ACL-006 and
MM13-4) and subjected to PKA-dependent in vitro phosphorylation. CFTR was detected as a specific band at approximately 140 kDa. The Suit-2
pancreatic adenocarcinoma cell line was used as a positive control. The band was not detectable when immune precipitation was performed with
isotypic antibodies (Mock). Lower Panel: Confocal microscopy analysis performed using the 13-1 antibody on monocytes derived from subjects
carrying a truncated (R1162X/R1162X) and wild type forms of CFTR. Membrane localization is detected in WT monocytes while R1162X/R1162X ones
display a disorganized distribution of the signal. The bar indicates 10 mM (one experiment of 3 performed).
doi:10.1371/journal.pone.0022212.g002
A New Blood Test for Cystic Fibrosis
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22212
A New Blood Test for Cystic Fibrosis
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22212
of association between the values of CF-index and CFTR mutation
class (p = 0.79), as shown in Figure 5. Interpretation of data did
not change considering other time points after at least 15 min of
recording instead of the last 5 min (data not shown).
Comparison among NPD measurements and monocyte
test
We wanted to evaluate whether the results of the monocyte tests
could identify correctly the patients found positive to an
established diagnostic test measuring CFTR-dependent activity
like NPD, a CFTR functional test based on the recording of Vm
on epithelial cells of the upper respiratory tract. This test, unlike
the monocyte test, is performed in vivo in the nostrils of
collaborative individuals and requires that the patients are free
of diseases affecting the test area. We evaluated the correlation
between the NPD test results and the CF-index in 32 participants
(20 CF, 4 HTZ and 8 controls) for whom a blood sample was
obtained at the time of the NPD test. In order to be able to
perform this analysis we calculated the Wilschanski’s index that
permits to evaluate the results of NPD measurements [27].
The comparison between Wilschanski’s and CF-indexes shows
that there are two outliers for which the value of the Wilschanski’s
index is particularly high consistently with the responses to low-Cl
and isoprotenerol obtained in NPD tracings (Figure S2).
To reduce the influence of the two outliers, and due to the
distribution of the Wilschanski’s index, we decided to compute the
Spearman rank-order correlation coefficient, which resulted equal
to 20.57 (p= 0.0007). However, the scatter plot casts some doubts
on the use of the correlation coefficient to analyze such data. In
particular, the graph shows a clear separation in points: in the
upper-left quadrant defined by CF-index.0 and Wilschanski’s
index ,0.85 lay all the controls, whereas in the bottom-right
quadrant lay all the CF participants. We therefore preferred to
express the relation between our test and the NPD test in terms of
concordance rather than correlation. We dichotomized the results,
using zero as positivity threshold for the CF-index (as suggested by
the plot of the index within groups) and we used 0.85 as positivity
threshold for the Wilschanski’s index (according to the validation
of this index in groups of CF and non-CF subjects tested in our
Center).
There was excellent concordance (Kappa statistic 0.93, 95%CI:
0.80–1.00) between the two test results: all the subjects were
classified in the same category except one (HTZ group), that
according to the index of Wilschanski was pathologic (index
value = 1.68), but according to the CF-index it was not (index
value = 94.2). Therefore the proportion of positive agreement [28]
was 97.6% and the proportion of negative agreement was 95.6%.
Table 1 summarizes the clinical and laboratory data of
patients, including the subjects that performed NPD test and
Figure 6 shows an example of the results obtained. We concluded
that the monocyte test could differentiate CF from control subjects
as the NPD test does.
Discussion
In this study, we have characterized the expression of CFTR in
human monocytes and described for the first time that these cells
express a CFTR variant that is recognized by specific antibodies
only following high-temperature denaturation. Moreover, we have
also shown that the functional evaluation of CFTR in these cells is
a potentially powerful tool for basic-translational research and
might find diagnostic applications. Monocytes appear to express a
CFTR corresponding to all the forms (defined as bands A, B and
C in the literature) detected in epithelial bronchial cells. In order to
detect CFTR expression in monocytes, cell lysate needs to be
treated at 95uC while denaturation at 40uC is necessary to detect
the antigen in epithelial cells. The same (95uC) treatment
performed in epithelial cells leads to an almost complete loss of
immuno-reactivity, with the notable exception of an incompletely
glycosylated isoform roughly corresponding to the apparent
molecule weight of band B. These results suggest that CFTR
processing is both quantitatively and qualitatively different in
monocytes as compared to both pancreatic and bronchial
epithelial cells.
The specificity of the result is further confirmed by the loss of
the specific band detected in normal monocytes in patients
homozygous for nonsense mutations known to affect CFTR
protein expression. Two CF patients heterozygous for nonsense
and homozygous for F508del mutations showed a severely
impaired expression of the band, in accordance with the predicted
phenotype.
Furthermore, despite the fact that the apparent MW recorded is
identical to that observed in WT and CF epithelial cells, we have
also excluded the possibility that an alternatively spliced isoform
missing exon 5 (30 amino acid) could be expressed in monocytes,
as reported for cardiac muscle where only a core glycosylated,
partially functional variant of about 140 kDa is expressed [26].
Accordingly RT-PCR performed using primers located in
sequences located in exons 4 and 6 amplified a cDNA fragment
predicted for the presence of exon 5 in both epithelial cells and
monocytes. This test also confirms the presence of CFTR
transcript in monocytes.
Whether this CFTR isoform expressed in monocytes is functional
has been confirmed by its proper membrane localization (as
detected by in vitro phosphorylation assay and confocal microscopy
analysis) and by single-cell membrane depolarization analysis. This
last assay confirms that, upon stimulation with CFTR agonists,
normal monocytes display a highly reproducible membrane
depolarization activity consistent with the expression of a fully
functional CFTR. This response is inhibited by treatment with a
specific CFTR inhibitor, is lost in monocytes derived from
individuals affected by CF and is reduced in HTZ subjects. The
spontaneous depolarization detected in monocytes derived from CF
patients was an unexpected finding and allows us to design an index
based on the differences recorded among the signals detected in the
various experimental conditions. The spontaneous depolarization is
Figure 3. Fluorescence-based CFTR functional analysis. Percentage of DiSBAC2(3) fluorescence variation (DF) is shown over time of addition of
the stimulus 8-Br-cAMP/forskolin/IBMX, according to the equation: DFt = [(Ft-F0)/F0]6100, where Ft and F0 are the fluorescence values in absence of
extracellular chloride at time t and at the time of addition of the stimulus respectively. Graphs show mean DFt and standard error. CFTR (inh)-172
(CFTR inhibitor) was added where indicated. Panel A: Suit-2 and CFPAC-1 pancreatic adenocarcinoma cell lines used as positive and negative
controls, respectively, at the recording times indicated on the x axis. Panel B: Same as panel A using purified human monocytes of non-CF (a), CF (b)
and HTZ (c) donors. (d) Differences between the maximum fluorescence value obtained under stimulation and the matching fluorescence value of
vehicle (CF-index). CF group showed values of CF-index significantly lower (median: 270.2, IQR: 2113.7;247.5) both than the HTZ group (median:
50.5; IQR: 17.8, 84.7) and the non-CF group (median: 113.3, IQR: 57.3, 147.3), both p,0.001 (***); also the difference found between the non-CF and
HTZ groups was statistically significant (p = 0.015, *).
doi:10.1371/journal.pone.0022212.g003
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Table 1. Clinical information and laboratory data of the CF patients enrolled in the study.
Case Gender
Age at
diagnosis
(years) CFTR genotype*
Age
(years)
Sweat Cl-
mEq/L**
FEV1 %
mean values
2009 Pa PI
NPD
results*** CF-index
1 F 0 3132delTG 1497delGG 34 129 75 yes yes nd 222,10
2 F 0 R1162X R1162X 43 144 52 yes yes nd 229,65
3 M 0 R1162X R1162X 10 102 59 no yes 1,02 210,18
4 M 0 R1162X R1162X 25 115 81 no yes 1,07 267,11
5 M 7 G542X 711+5 G.A 24 105 59 yes yes nd 25,84
6 M 1 CFTRdele1 G542X 36 107 22 yes yes nd 2113,92
7 M 0 G542X G542X 16 110 71 yes yes 0,97 280,20
8 F 1 Q552X CFTRdele17a-18 35 99 72 yes yes 2,08 2219,81
9 M 16 R1162X 3849+10 Kb C.T 42 74 43 yes no 1,02 271,47
10 M 0 R1162X R1162X 32 105 45 yes yes 1,43 2114,67
11 M 1 F508del F508del 16 86 71 no yes nd 260,04
12 F 0 F508del F508del 16 88 118 no yes nd 248,20
13 M 0 F508del F508del 33 118 51 yes yes nd 265,49
14 M 7 F508del F508del 37 89 37 yes yes nd 2359,82
15 F 0 F508del F508del 27 118 71 yes yes nd 267,26
16 F 8 1717-1 G.A F508del 38 140 74 yes yes nd 2136,80
17 F 0 R1158X F508del 32 95 60 yes yes 1,77 228,31
18 M 7 G542X F508del 39 110 46 yes yes nd 247,52
19 M 0 Q39X F508del 17 101 79 no yes 1,11 264,20
20 F 1 R1162X F508del 41 188 60 no yes 0,94 296,73
21 M 13 3849+10 Kb C.T F508del 24 76 78 yes no 4,67 26,33
22 M 0 W1282X 621+1G.T 33 119 77 yes yes 1,27 242,74
23 F 4 R553X 2789+5 G.A 31 92 44 yes no 7,4 260,94
24 F 11 F508del R553X 39 116 55 yes yes nd 2113,67
25 M 12 F508del 3849+10 Kb C.T 27 51 71 yes no 1,12 298,84
26 F 0 F508del G542X 19 109 109 yes yes nd 2173,24
27 F 0 F508del R1162X 32 94 86 yes yes 1,34 270,16
28 F 0 F508del W57X (TAG) 27 99 78 yes yes 1,21 269,33
29 M 0 F508del Q552X 24 94 41 yes yes 1,50 272,75
30 M 20 F508del 3849+10 Kb C.T 43 58 60 no no 1,13 2112,56
31 M 0 F508del R1162X 12 99 65 no yes 2,14 280,92
32 M 4 F508del 3849+10 Kb C.T 17 60 100 no no nd 2121,31
33 F 1 F508del 1717-1 G.A 26 105 73 yes yes 2,05 255,66
34 F 11 F508del 3849+10 Kb C.T 40 85 59 yes no nd 2152,23
35 F 4 F508del 1717-1 G.A 44 130 97 yes yes nd 2116,56
36 M 13 F508del 3849+10 Kb C.T 43 70 65 yes no CF 265,10
37 F 19 F508del unknown 29 95 100 no no nd 240,53
38 M 6 F508del unknown 15 92 87 yes no nd 270,17
39 F 0 G542X N1303K 34 108 97 yes yes nd 296,14
40 M 50 G1249R IVS8 T5TG12 50 61 74 no no nd 2199,15
41 F 10 2183 AA.G IVS8 T5TG15/T7TG10 45 79 29 yes no 1,9 286,27
42 F 1 G85E unknown 43 120 107 yes no nd 249,21
43 F 0 3272-26 A.G I507del 21 113 88 no no nd 236,79
44 M 8 F508del D1152H 10 77 107 no no nd 210,85
*Cystic Fibrosis mutation database reference: http://www3.genet.sickkids.on.ca/cftr/app.
**As determined by Sweat test performed according to the Gibson and Cooke method (Sweat testing: Sample Collection and Quantitative Analysis – Approved
Guideline – Second Edition – The National Committee for Clinical Laboratory Standards (NCCLS) – document C34 A2 [ISBN – 56238 – 407 – 4]; USA . Pa: Pseudomonas
Aeruginosa chronic infection according to Doring et al [44]; PI (pancreatic insufficiency requiring oral enzyme supplementation); NPD: Nasal Potential Difference; nd: not
done; CF: cystic fibrosis.
***Numbers indicate NPD values calculated as described by Wilschanski et al. [27].
doi:10.1371/journal.pone.0022212.t001
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inhibited by treatment with the sodium channels blocker amiloride
and by treatment with a cAMP analog as well as the CFTR
inhibitor 172. Cross-talk among epithelial sodium channel (ENaC)
and CFTR has been described in the literature and CFTR is known
to regulate other ion channels within the cell. Of note is the
observation that ENaC is differently regulated in various organs
[29]. Data from various laboratories have shown that ENaC is
inhibited by CFTR through incompletely understood mechanisms,
suggesting that the spontaneous depolarization we detected could be
associated to the loss of CFTR inhibitory signal in CF monocytes
leading to the hyperactivation of ENaC channels [29]. This
interpretation is supported by the effect of amiloride that completely
prevents the depolarization recorded in untreated CF monocytes.
The inhibition of spontaneous depolarization is also achieved by
treatment of monocytes with a cAMP analog. In this case inhibition
of ENaC and/or other sodium channels might occur through
CFTR-independent mechanisms whose detailed characterization
was beyond the scope of this study. Loss of increased sodium
absorption is considered very important in humans for the
pathogenesis of CF disease as well as for diagnosis using sweat test
(ST) and NPD. However this defect was not detected in newborn
porcine cystic fibrosis airway epithelia [30]. It would be interesting
to test monocytes also in this very recent CF animal model.
The extents of activation of normal monocytes coupled to the
loss of response by CF monocytes allow devising an index able to
distinguish between CF and non-CF subjects. Of note is the
observation that this test might have a unique feature among
currently used functional tests such as ST, NPD and ICM, which
can discriminate between CF and healthy subjects [31,32]. In fact
the monocytes test appears capable to distinguish also the
population of monocytes derived from heterozygous subjects from
both normal and CF subjects. Of course this perspective will be
further addressed by enrolling more subjects, in particular
heterozygous for CFTR mutations even if ROC curve analysis
indicate that the difference recorded is unlikely to become of
clinical interest. We noticed that genotypes, when grouped
according to functional classes, result in similar values of CF-
index. This finding suggests that while this test appears capable to
identify loss of protein function it fails to discriminate patients
according to mutation types. As a relevant case in the presence of
3849+10 kbC.T or 2789+5G.A mutations we have measured
comparable CF indexes values as in other nonsense mutations
abolishing functional CFTR expression. This case does not detract
in any way the potential applications of this test as no other
Figure 5. Distribution of CF-index by group of CFTR mutation.
The CF subjects were categorized into 4 groups according to CFTR
mutation. The five classes of CFTR mutation as described by Welsh and
Smith [42] were adopted for this study according to the information
available in the CFTR mutations database (http://www.genet.sickkids.
on.ca/cftr/app). No significant differences were found between the
mean values of CF-index in the 4 different genotype groups
(homozygous class I, homozygous II, heterozygous class I and II and
the other class mutations) on the basis of one-way ANOVA performed
on normal scores computed on CF-index ranks.
doi:10.1371/journal.pone.0022212.g005
Figure 4. Amiloride inhibits the spontaneous depolarization signal detected in CF monocytes. Non-CF monocytes were analyzed with
vehicle alone and in the presence of amiloride (left panel). Amiloride does not affect baseline. Amiloride treatment induces a reduction of
spontaneous depolarization in CF subjects (right panel) to an extent overlapping to the effect of the addition of the stimulus. The effect of CFTR (inh)-
172 after 15 minutes after addition of the stimulus in non-CF monocytes is also shown (left).
doi:10.1371/journal.pone.0022212.g004
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functional test currently employed has the capacity to discriminate
among the different genotypes but can only discriminate among
healthy and CF individuals. We need to consider, however, the
possibility that CFTR expressed in monocytes might be processed
differently from epithelia and sweat duct cells. The role of CFTR
in macrophages has been reported as a modulator of the
inflammatory process in CF (reviewed in [33]). As monocytes
represent macrophage precursors present in the bloodstream their
role could be different than that of ‘‘innocent bystander’’, as such
monocyte test might target a relevant function involved in the
pathogenesis of CF disease. Also differential protein expression
levels in various cell types is not unusual in selected cases, such as
in individuals carrying a splicing CFTR mutation, 3849+10 kb
CRT where the regulation of alternative splice site selection may
be an important mechanism underlying partial penetrance in CF
[34].
CFTR activity in monocytes may or may not be correlated with
CFTR activity in other tissues. Our results in monocytes show
concordance with airways epithelial cells by comparison of CF
index with Wilschanski’s index. In the presence of mutations
known to be associated with normal-borderline sweat test (ST) CF
index was negative (table 1 and recent unpublished data).
However in these cases the absence of correlation of defective
CFTR activity in monocytes with CFTR activity in sweat gland
cells indicate the potential capability of the monocyte test to
correctly identify CF subjects in difficult cases.
These results might have relevant clinical implications as,
although the genetic test represents a major improvement in our
capability to diagnose CF, ST represents the standard procedure
to confirm a CF diagnosis in the presence of CF symptoms/
positive CF newborn screening [35,36]. According to recent
guidelines for diagnosis of CF, ST alone may not be utilized to
diagnose CF [36]. Even the combination of ST and genetic test is
not always sufficient to diagnose CF. Therefore functional tests
performed directly on epithelial cells such as NPD (nasal mucosa)
or ICM (rectal biopsies) are required for CF diagnosis [37]. The
usefulness of functional tests other than ST has been established in
recent best practice guidelines [38]. Despite many efforts the issue
of standardization of functional assays (NPD and ICM) is still a
matter of discussion [19,21]: efforts to resolve this important issue
are currently ongoing within both European Cystic Fibrosis
Society and Cystic Fibrosis Foundation. For these reasons, the
proposal of a new functional assay capable to complement the
above-mentioned ones can be of interest in the field. Another
potential application of the assays we describe is in translational
research. For instance, as the variables we analyzed targets
Figure 6. Nasal potential difference analysis (NPD) confirms the results obtained in monocytes isolated from the same subjects.
Typical NPD measurements are shown in the upper panel: the agents indicated at the bottom were added at the times (minutes) shown on the x axis.
On the y axis, PD is expressed in mV. The graphs represent a typical value obtained from the analysis of both nostrils in each subject. The presence of
functional CFTR in non-CF and HTZ subjects is indicated by the marked response to the absence of chloride and the addition of isoproterenol, which
is undetectable in CF subjects. Moreover, depolarization in the presence of amiloride is more consistent in CF than in non-CF subjects, as the cellular
influx of sodium is increased in CF versus non-CF. Depolarization in the presence of amiloride is higher in CF than in non-CF and HTZ subjects in
keeping with the increased cellular sodium influx in CF versus non-CF. Increased polarization is induced by no chloride and isoproterenol in the
presence of functional CFTR in non-CF and HTZ subjects, but not in the presence of defective CFTR, as in CF subjects. ATP has been utilized as a
stimulus for alternative non-CFTR chloride secretory pathways as Ca++ activated chloride channels [43]. The monocytes of the same subjects were
tested, and the results are shown as indicated in B. Fluorescence analysis in monocytes shows that induction of depolarization was detected in non-
CF and, to a lesser extent, in HTZ subjects but not in CF patients.
doi:10.1371/journal.pone.0022212.g006
A New Blood Test for Cystic Fibrosis
PLoS ONE | www.plosone.org 11 July 2011 | Volume 6 | Issue 7 | e22212
myeloid cells whose involvement in the pathogenesis of CF is
becoming increasingly recognized in the field [9,39,40], this
approach might represent a valuable marker of the therapeutic
effects of CFTR-targeted drugs in CF patients and they might be
used to test the efficacy of any drugs targeting mutations affecting
CFTR expression (by western blot) or function (by cell membrane
depolarization assay), such as the ones currently under clinical
evaluation [41]. In this regard, it is of interest to note that the
assays described provided CF values (a negative CF-index) in all
the cased diagnoses as CF. We demonstrated that in similar
experimental condition both nasal epithelial cells and monocytes
can be tested for CFTR function in vivo and in vitro, respectively
as applied on 21 CF subjects. In addition to its apparent reliability,
testified by these results, some unique advantages can be identified
for the monocyte test:
1) It can be performed within a few hours after blood collection.
In this case, it is likely that cells removed from the blood
might better maintain the effects of any drug previously
administered to the patient proving evidence of in vivo effects.
2) It is easily repeatable with a minimal discomfort and risk for
the patient, and could thus allow a time-course evaluation of
effects of any particular therapy on CFTR expression or
functional activity, whatever is appropriate according to the
treatment.
The monocyte assay, once fully validated by independent
research centers, could thus provide a significant advantage in
ongoing and future clinical trials. Although the data from the
literature, the whole body of antibody and mRNA expression data
combined with the use of samples derived from CFTR-defective
individuals indicate with high confidence the expression and the
function of CFTR in human monocytes, the assessment of CFTR
expression by antibody-independent techniques might be useful to
further enhance the confidence of our findings. Future directions
of these studies include the evaluation of this test in various
pulmonary diseases, the use of cryopreserved monocytes, of new
specific fluorescent probes and the development of an automated
reading system that might expedite the analysis.
Supporting Information
Figure S1 ROC curve showing the joint variation of
sensitivity and specificity at different thresholds of
CF-index to discriminate HTZ from non-CF partici-
pants. The ROC curve was drawn computing the sensitivity and
specificity in classifying participants as heterozygotes or non-CF
according to different CF-index thresholds. Although the AUC is
0.81 (95%CI: 0.67;0.95), the graph reveals the poor ability of CF-
index to separate the two groups: none of the thresholds yielded
satisfactory values of sensitivity and specificity. Their maximum
joint values are 83.9% and 63.6% respectively.
(TIF)
Figure S2 Scatter-plot of CF-index against Wilschanski
index values. The graph shows the presence of two outliers for
which the value of the Wilschanski’s index is particularly high,
consistently with the responses to low-Cl and isoprotenerol
obtained in NPD tracings. The graph shows a clear separation
into groups: in the upper-left quadrant defined by CF-index.0
and Wilschanski’s index ,0.85 lay all the controls, whereas in the
bottom-right quadrant lay all the CF participants.
(TIF)
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